MARKET

NBRV

NBRV

Nabriva
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.6151
-0.0450
-6.82%
Closed 17:43 03/27 EDT
OPEN
0.6601
PREV CLOSE
0.6601
HIGH
0.6817
LOW
0.6000
VOLUME
2.37M
TURNOVER
--
52 WEEK HIGH
3.190
52 WEEK LOW
0.4975
MARKET CAP
58.20M
P/E (TTM)
-0.4544
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of NBRV and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 7 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average NBRV stock price target is 3.833 with a high estimate of 7.00 and a low estimate of 1.000.

EPS

NBRV News

More
  • Berenberg sees 93% upside in Alnylam in premarket analyst action
  • Seeking Alpha - Article · 03/19 11:34
  • The Daily Biotech Pulse: Setback For DBV In Peanut Allergy Patch Review, Roche Starts Coronavirus Test Shipment, Regeneron Aims For 'Cocktail' COVID-19 Treatment
  • Benzinga · 03/17 15:38
  • Benzinga's Top Upgrades, Downgrades For March 17, 2020
  • Benzinga · 03/17 14:39
  • Benzinga's Top Upgrades, Downgrades For March 17, 2020
  • Benzinga · 03/17 14:33

Industry

Biotechnology & Medical Research
-2.43%
Pharmaceuticals & Medical Research
-0.87%

Hot Stocks

Symbol
Price
%Change

About NBRV

Nabriva Therapeutics plc is a clinical stage biopharmaceutical company. The Company is engaged in engaged in the research and development of novel anti-infectives to treat serious infections, with a focus on the pleuromutilin class of antibiotics. The Company’s medicinal chemistry has enabled targeted discovery of novel pleuromutilins, including both intravenous and oral formulations of its lead product candidate, lefamulin. Lefamulin is a novel semi-synthetic pleuromutilin antibiotic with the potential to be the first-in-class available for systemic administration in humans. Lefamulin is being evaluated in two global, registrational Phase III clinical trials in patients with moderate to severe community-acquired bacterial pneumonia (CABP).It seeks to further pursue development of lefamulin for additional indications, including the treatment of acute bacterial skin and skin structure infections (ABSSSI), and is developing a formulation of lefamulin appropriate for pediatric use.
More

Webull offers kinds of Nabriva Therapeutics PLC - ADR stock information, including NASDAQ:NBRV real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NBRV stock news, and many more online research tools to help you make informed decisions.